#1 Clinical Trials Search in Europe

Phosphocreatine Sodium

This article discusses a clinical trial investigating the use of Phosphocreatine Sodium (PCr) in high-risk cardiac surgery patients. The study aims to evaluate whether PCr can improve myocardial protection compared to a placebo in patients undergoing cardiac surgical procedures or heart valve prosthesis implantation. The trial explores the potential benefits of PCr in enhancing heart energy metabolism and reducing complications associated with cardiac surgery.

Table of Contents

What is Phosphocreatine?

Phosphocreatine, also known by its brand name Neoton, is a substance that plays a crucial role in the energy metabolism of the heart[1]. It’s being studied as a potential protective agent for patients undergoing high-risk cardiac surgery. Phosphocreatine is part of the body’s natural energy system, particularly important in tissues that require a lot of energy, like the heart.

Medical Conditions Targeted

The research on phosphocreatine is primarily focused on patients undergoing:

  • Cardiac Surgical Procedures: These are operations performed on the heart, which can be very demanding on the body and the heart itself.
  • Heart Valve Prosthesis Implantation: This is a specific type of heart surgery where artificial heart valves are implanted to replace damaged or diseased natural heart valves[1].

How Phosphocreatine Works

Phosphocreatine is part of the heart’s energy system. During heart surgery, the heart may experience stress and lack of oxygen, which can lead to damage. Phosphocreatine is thought to help protect the heart by:

  • Providing a quick source of energy for the heart cells
  • Helping to maintain the heart’s normal function during and after surgery
  • Potentially reducing damage to the heart muscle[1]

How Phosphocreatine is Administered

In the current research, phosphocreatine is being administered to patients in several ways:

  1. Before surgery: 2 grams of phosphocreatine is given intravenously (through a vein) after anesthesia is started.
  2. During surgery: It’s added to the cardioplegia solution (a special fluid used to protect the heart during surgery when its normal blood supply is interrupted).
  3. After surgery: It’s given again just after the heart starts beating on its own, and once more after the patient is admitted to the Intensive Care Unit (ICU)[1].

Current Research Focus

The ongoing research is primarily interested in understanding:

  • Whether phosphocreatine can improve heart protection in high-risk patients undergoing cardiac surgery
  • What the best ways are to measure the effectiveness of phosphocreatine in future larger studies[1]

Potential Benefits

While the research is still ongoing, scientists are looking at several potential benefits of using phosphocreatine. These include:

  • Reduced heart damage (measured by lower levels of a protein called Troponin I in the blood)
  • Less need for medications to support heart function after surgery
  • Fewer heart rhythm problems after surgery
  • Better heart function after surgery
  • Potentially shorter stays in the ICU and hospital
  • Possibly lower risk of complications like kidney problems[1]

Ongoing Research

The current study is what’s known as a “randomized, double-blind, placebo-controlled trial.” This means:

  • Randomized: Patients are randomly assigned to either receive phosphocreatine or a placebo (a harmless substance with no medical effect).
  • Double-blind: Neither the patients nor the doctors directly involved in their care know who is receiving phosphocreatine and who is receiving the placebo.
  • Placebo-controlled: The effects of phosphocreatine are being compared to those of a placebo to determine if it truly provides benefits[1].

This type of study design helps ensure that the results are as accurate and unbiased as possible. The researchers will be closely monitoring patients for about 4 weeks after their surgery to understand the effects of phosphocreatine.

Aspect Details
Study Type Randomized, double-blind, placebo-controlled exploratory pilot clinical trial
Intervention Phosphocreatine Sodium (PCr) vs. Placebo (5% glucose solution)
Participant Group High-risk patients undergoing cardiac surgery or heart valve prosthesis implantation
Primary Outcome Peak concentration of Troponin I (marker of heart muscle damage)
Key Secondary Outcomes Need for inotropic agents, incidence of arrhythmias, left ventricular ejection fraction, kidney function, ICU and hospital stay duration, 30-day mortality
Administration of PCr Four stages: after anesthesia induction, in cardioplegia solution, after heart recovery, and after ICU admission
Study Rationale To investigate if PCr improves myocardial protection in high-risk cardiac surgery patients and determine best research endpoints for future trials

FAQ

  • What is Phosphocreatine Sodium and why is it being studied in cardiac surgery? Phosphocreatine Sodium (PCr) is a compound that plays an important role in the heart's energy system. It's being studied because it may help protect the heart during high-risk cardiac surgeries by improving the heart's energy metabolism.
  • How is Phosphocreatine Sodium administered in this clinical trial? In this trial, PCr is administered at four different times: after anesthesia induction, added to the cardioplegia solution, after heart recovery following aorta declamping, and after ICU admission. It's given intravenously in various doses mixed with glucose solution.
  • What are the main outcomes being measured in this study? The primary outcome is the peak concentration of Troponin I, a marker of heart muscle damage. Secondary outcomes include the need for inotropic agents, incidence of arrhythmias, left ventricular ejection fraction, kidney function, duration of ICU and hospital stay, and 30-day mortality.
  • Who are the participants in this clinical trial? The participants are high-risk patients scheduled for cardiac surgery, specifically those undergoing cardiac surgical procedures or heart valve prosthesis implantation.
  • How does this study compare Phosphocreatine Sodium to a placebo? The study is randomized and double-blind, meaning participants are randomly assigned to either receive PCr or a placebo (5% glucose solution). The placebo is administered in the same manner and timing as PCr to maintain the blinding of the study.

Ongoing Clinical Trials on Phosphocreatine Sodium

  • Study on the Effect of Phosphocreatine Sodium and Sodium Chloride in Patients Treated by Medical Emergency Teams with Conditions like Rapid Breathing or Low Blood Pressure

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Phosphocreatine (PCr): A compound that plays a crucial role in the energy metabolism of the heart, helping to store and transfer energy in muscle cells.
  • Myocardial Protection: Strategies or treatments used to protect the heart muscle from damage during cardiac surgery or other stressful conditions.
  • Cardioplegia: A solution used to stop the heart temporarily during cardiac surgery, protecting it from damage.
  • Troponin I: A protein released into the blood when heart muscle is damaged, used as a marker to detect heart injury.
  • Inotropic Agents: Medications that change the force of heart muscle contractions, often used to support heart function during or after surgery.
  • Left Ventricular Ejection Fraction: A measurement of how much blood the left ventricle pumps out with each contraction, used to assess heart function.
  • Acute Kidney Injury: A sudden decrease in kidney function, which can be a complication of major surgery or critical illness.
  • Sequential Organ Failure Assessment (SOFA) Score: A scoring system used to track a patient's status during their stay in an intensive care unit (ICU).
  • Arrhythmias: Irregular heartbeats or abnormal heart rhythms, which can occur as a complication of heart surgery.
  • Randomized Controlled Trial (RCT): A type of scientific experiment where participants are randomly assigned to different treatment groups to compare outcomes.

References

  1. https://clinicaltrials.gov/study/NCT02757443